share_log

Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target

Benzinga ·  Aug 9 10:04  · Ratings

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment